Spotlight on Urology
New Choices in Targeted Treatments for Advanced or Metastatic Urothelial Carcinoma: Plot Your Own Course
StartActivity Details
Expires: November 23, 2021
Accredited By
Target Audience
This educational initiative has been designed for genitourinary oncologists, medical oncologists, surgical oncologists, radiologists, urologists, nurse practitioners (NPs), physician assistants (PAs), clinical nurse specialists (CNSs), advanced practice nurses (APNs), oncology clinical nurses (OCNs), and clinical oncology pharmacists (BCOPs) involved in the care and coordination of patients with urothelial carcinoma (UC).
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of UC
- Outline efficacy and safety findings from key clinical trials of approved and investigational novel treatments developed for the treatment of advanced or metastatic UC (mUC)
Statement of Educational Need
In advanced or metastatic urothelial carcinoma (UC) a heavily cytotoxic “sledgehammer” approach has traditionally been used. Platinum-based chemotherapy is still the preferred first-line approach. But this non-specific cytotoxic treatment is often intolerable for the typically older UC patient.
Until recently, there were no second-line options beyond the chemotherapeutic sledgehammer. Today, treatments with more selective mechanisms of action take advantage of fresh translational insights into UC.
These novel therapeutics offer more efficient targeting for patients who have run out of options. But for clinicians, the introduction of these agents complicates an already complex condition. This activity will guide them in selecting and using these options.
In this case-based activity you will navigate a simulated patient case, making clinical decisions when prompted. Feedback regarding your decisions will be provided as you move through the case.
Co-Chairs
Professor, Centre of Experimental Cancer Medicines
Bart’s Cancer Institute
St. Bartholomew’s Hospital
London, United Kingdom
Chief of Clinical Trials
Department of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, Tennessee
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education, Inc requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Thomas Powell, MD:
Consulting Fees: AstraZeneca, Bristol Myers Squibb, Exelixis,
Incyte, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer, Seattle
Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and
Roche
Contracted Research: AstraZeneca, Roche, Bristol Myers
Squibb, Exelixis, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer,
Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and
Eisai
Other: Expenses/Travel/Accommodation: Roche, Pfizer, Merck
Sharp & Dohme, AstraZeneca, and Ipsen
Brian Rini, MD:
Consulting Fees: Merck, Pfizer, Bristol Myers Squibb, Aravive, AVEO
Pharmaceuticals, GlaxoSmithKline
Contracted Research: Merck, Bristol Myers Squibb, Exelixis,
Pfizer, AstraZeneca
Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
Integrity Continuing Education, Inc is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
Designation of Credit
Integrity Continuing Education, Inc designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of November 23, 2020 through November 23, 2021, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc., EMD, Serono, Inc., and Pfizer, Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from EMD Serono, Inc. and Pfizer, Inc.
Activity Details
Expires: November 23, 2021
Accredited By
Target Audience
This educational initiative has been designed for genitourinary oncologists, medical oncologists, surgical oncologists, radiologists, urologists, nurse practitioners (NPs), physician assistants (PAs), clinical nurse specialists (CNSs), advanced practice nurses (APNs), oncology clinical nurses (OCNs), and clinical oncology pharmacists (BCOPs) involved in the care and coordination of patients with urothelial carcinoma (UC).
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of UC
- Outline efficacy and safety findings from key clinical trials of approved and investigational novel treatments developed for the treatment of advanced or metastatic UC (mUC)
Statement of Educational Need
In advanced or metastatic urothelial carcinoma (UC) a heavily cytotoxic “sledgehammer” approach has traditionally been used. Platinum-based chemotherapy is still the preferred first-line approach. But this non-specific cytotoxic treatment is often intolerable for the typically older UC patient.
Until recently, there were no second-line options beyond the chemotherapeutic sledgehammer. Today, treatments with more selective mechanisms of action take advantage of fresh translational insights into UC.
These novel therapeutics offer more efficient targeting for patients who have run out of options. But for clinicians, the introduction of these agents complicates an already complex condition. This activity will guide them in selecting and using these options.
In this case-based activity you will navigate a simulated patient case, making clinical decisions when prompted. Feedback regarding your decisions will be provided as you move through the case.
Co-Chairs
Professor, Centre of Experimental Cancer Medicines
Bart’s Cancer Institute
St. Bartholomew’s Hospital
London, United Kingdom
Chief of Clinical Trials
Department of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, Tennessee
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education, Inc requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Thomas Powell, MD:
Consulting Fees: AstraZeneca, Bristol Myers Squibb, Exelixis,
Incyte, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer, Seattle
Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and
Roche
Contracted Research: AstraZeneca, Roche, Bristol Myers
Squibb, Exelixis, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer,
Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and
Eisai
Other: Expenses/Travel/Accommodation: Roche, Pfizer, Merck
Sharp & Dohme, AstraZeneca, and Ipsen
Brian Rini, MD:
Consulting Fees: Merck, Pfizer, Bristol Myers Squibb, Aravive, AVEO
Pharmaceuticals, GlaxoSmithKline
Contracted Research: Merck, Bristol Myers Squibb, Exelixis,
Pfizer, AstraZeneca
Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
Integrity Continuing Education, Inc is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
Designation of Credit
Integrity Continuing Education, Inc designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of November 23, 2020 through November 23, 2021, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc., EMD, Serono, Inc., and Pfizer, Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from EMD Serono, Inc. and Pfizer, Inc.
Urology Presentations
New Choices in Targeted Treatments for Advanced or Metastatic Urothelial Carcinoma: Plot Your Own Course
StartActivity Details
Expires: November 23, 2021
Accredited By
Target Audience
This educational initiative has been designed for genitourinary oncologists, medical oncologists, surgical oncologists, radiologists, urologists, nurse practitioners (NPs), physician assistants (PAs), clinical nurse specialists (CNSs), advanced practice nurses (APNs), oncology clinical nurses (OCNs), and clinical oncology pharmacists (BCOPs) involved in the care and coordination of patients with urothelial carcinoma (UC).
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of UC
- Outline efficacy and safety findings from key clinical trials of approved and investigational novel treatments developed for the treatment of advanced or metastatic UC (mUC)
Statement of Educational Need
In advanced or metastatic urothelial carcinoma (UC) a heavily cytotoxic “sledgehammer” approach has traditionally been used. Platinum-based chemotherapy is still the preferred first-line approach. But this non-specific cytotoxic treatment is often intolerable for the typically older UC patient.
Until recently, there were no second-line options beyond the chemotherapeutic sledgehammer. Today, treatments with more selective mechanisms of action take advantage of fresh translational insights into UC.
These novel therapeutics offer more efficient targeting for patients who have run out of options. But for clinicians, the introduction of these agents complicates an already complex condition. This activity will guide them in selecting and using these options.
In this case-based activity you will navigate a simulated patient case, making clinical decisions when prompted. Feedback regarding your decisions will be provided as you move through the case.
Co-Chairs
Professor, Centre of Experimental Cancer Medicines
Bart’s Cancer Institute
St. Bartholomew’s Hospital
London, United Kingdom
Chief of Clinical Trials
Department of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, Tennessee
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education, Inc requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Thomas Powell, MD:
Consulting Fees: AstraZeneca, Bristol Myers Squibb, Exelixis,
Incyte, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer, Seattle
Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and
Roche
Contracted Research: AstraZeneca, Roche, Bristol Myers
Squibb, Exelixis, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer,
Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and
Eisai
Other: Expenses/Travel/Accommodation: Roche, Pfizer, Merck
Sharp & Dohme, AstraZeneca, and Ipsen
Brian Rini, MD:
Consulting Fees: Merck, Pfizer, Bristol Myers Squibb, Aravive, AVEO
Pharmaceuticals, GlaxoSmithKline
Contracted Research: Merck, Bristol Myers Squibb, Exelixis,
Pfizer, AstraZeneca
Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
Integrity Continuing Education, Inc is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
Designation of Credit
Integrity Continuing Education, Inc designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of November 23, 2020 through November 23, 2021, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc., EMD, Serono, Inc., and Pfizer, Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from EMD Serono, Inc. and Pfizer, Inc.
Activity Details
Expires: November 23, 2021
Accredited By
Target Audience
This educational initiative has been designed for genitourinary oncologists, medical oncologists, surgical oncologists, radiologists, urologists, nurse practitioners (NPs), physician assistants (PAs), clinical nurse specialists (CNSs), advanced practice nurses (APNs), oncology clinical nurses (OCNs), and clinical oncology pharmacists (BCOPs) involved in the care and coordination of patients with urothelial carcinoma (UC).
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of UC
- Outline efficacy and safety findings from key clinical trials of approved and investigational novel treatments developed for the treatment of advanced or metastatic UC (mUC)
Statement of Educational Need
In advanced or metastatic urothelial carcinoma (UC) a heavily cytotoxic “sledgehammer” approach has traditionally been used. Platinum-based chemotherapy is still the preferred first-line approach. But this non-specific cytotoxic treatment is often intolerable for the typically older UC patient.
Until recently, there were no second-line options beyond the chemotherapeutic sledgehammer. Today, treatments with more selective mechanisms of action take advantage of fresh translational insights into UC.
These novel therapeutics offer more efficient targeting for patients who have run out of options. But for clinicians, the introduction of these agents complicates an already complex condition. This activity will guide them in selecting and using these options.
In this case-based activity you will navigate a simulated patient case, making clinical decisions when prompted. Feedback regarding your decisions will be provided as you move through the case.
Co-Chairs
Professor, Centre of Experimental Cancer Medicines
Bart’s Cancer Institute
St. Bartholomew’s Hospital
London, United Kingdom
Chief of Clinical Trials
Department of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, Tennessee
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education, Inc requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Thomas Powell, MD:
Consulting Fees: AstraZeneca, Bristol Myers Squibb, Exelixis,
Incyte, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer, Seattle
Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and
Roche
Contracted Research: AstraZeneca, Roche, Bristol Myers
Squibb, Exelixis, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer,
Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and
Eisai
Other: Expenses/Travel/Accommodation: Roche, Pfizer, Merck
Sharp & Dohme, AstraZeneca, and Ipsen
Brian Rini, MD:
Consulting Fees: Merck, Pfizer, Bristol Myers Squibb, Aravive, AVEO
Pharmaceuticals, GlaxoSmithKline
Contracted Research: Merck, Bristol Myers Squibb, Exelixis,
Pfizer, AstraZeneca
Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
Integrity Continuing Education, Inc is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
Designation of Credit
Integrity Continuing Education, Inc designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of November 23, 2020 through November 23, 2021, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc., EMD, Serono, Inc., and Pfizer, Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from EMD Serono, Inc. and Pfizer, Inc.
Navigating the Prostate Cancer Disease Continuum - Evolving Strategies in the Management of HSPC and CRPC
StartActivity Details
1.0 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-provided By
Target Audience
This activity is designed to meet the educational needs of urologists, and oncologists, as well as nurses, NPs, PAs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.
Learning Objectives
After completing this program, participants should be able to:
- Evaluate the latest clinical data on efficacy, safety, and sequencing considerations for hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies for patients with HSPC and CRPC
- Identify ongoing and planned clinical trials for prostate cancer patients across the disease continuum and refer appropriate patients to trials with novel therapies or in combination
- Implement the latest best-practice treatment strategies for patients with HSPC and CRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for prostate cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with prostate cancer, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Sectional Head Medical Oncology
Deputy Director, University of Virginia Cancer Center
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, VA
Conflict of Interest Policy/Disclosure Statement
Dr. Dreicer has served on advisory boards for Eisai, Janssen, Seattle Genetics, Genetech/Roche, Azuri, Astra Zeneca, Orion, and Novartis.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity has been supported by an educational grant from Astellas and Medivation, Inc., a Pfizer Company, Genomic Health, Janssen Biotech, Inc., and Sanofi Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
Activity Details
1.0 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-provided By
Target Audience
This activity is designed to meet the educational needs of urologists, and oncologists, as well as nurses, NPs, PAs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.
Learning Objectives
After completing this program, participants should be able to:
- Evaluate the latest clinical data on efficacy, safety, and sequencing considerations for hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies for patients with HSPC and CRPC
- Identify ongoing and planned clinical trials for prostate cancer patients across the disease continuum and refer appropriate patients to trials with novel therapies or in combination
- Implement the latest best-practice treatment strategies for patients with HSPC and CRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for prostate cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with prostate cancer, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Sectional Head Medical Oncology
Deputy Director, University of Virginia Cancer Center
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, VA
Conflict of Interest Policy/Disclosure Statement
Dr. Dreicer has served on advisory boards for Eisai, Janssen, Seattle Genetics, Genetech/Roche, Azuri, Astra Zeneca, Orion, and Novartis.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity has been supported by an educational grant from Astellas and Medivation, Inc., a Pfizer Company, Genomic Health, Janssen Biotech, Inc., and Sanofi Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.